Sustained AAV-mediated Dystrophin Expression in a Canine Model of Duchenne Muscular Dystrophy with a Brief Course of Immunosuppression.

Zejing Wang; Kuhr, Christian S.; Allen, James M.; Blankinship, Michael; Gregorevic, Paul; Chamberlain, Jeffrey S.; Tapscott, Stephen J.; Storb, Rainer

See page 1040Adeno-associated virus–based vector (AAV)–mediated gene delivery has been successful in some animal models of human disease such as the mdx mouse model of human Duchenne muscular dystrophy (DMD). However, recent evidence of immune-mediated loss of vector persistence in dogs and humans suggests that immune modulation might be necessary to achieve successful long-term transgene expression in these species. We have previously demonstrated that direct intramuscular injection of AAV2 or AAV6 in wild-type random-bred dogs resulted in a robust immune response to capsid or capsid-associated proteins. We now demonstrate that a brief course of immunosuppression with a combination of anti-thymocyte globulin (ATG), cyclosporine (CSP), and mycophenolate mofetil (MMF) is sufficient to permit long-term and robust expression of a canine micro-dystrophin (c-μ-dys) transgene in the skeletal muscle of a dog model for DMD (canine X-linked muscular dystrophy, or cxmd dog) and that its expression restored localization of components of the dystrophin-associated protein complex at the muscle membrane. This protocol has potential applications to human clinical trials to enhance AAV-mediated therapies.Molecular Therapy (2007) 15 6, 1160–1166. doi:10.1038/sj.mt.6300161

DYSTROPHIN; DUCHENNE muscular dystrophy; IMMUNOSUPPRESSION; ADENOVIRUSES; GENE expression; GENE therapy

Molecular Therapy, 2007, Vol 15, Issue 6, p1160

1525-0016

Academic Journal

10.1038/sj.mt.6300161